Home Cart Sign in  
Chemical Structure| 194413-58-6 Chemical Structure| 194413-58-6

Structure of (Z)-Semaxanib
CAS No.: 194413-58-6

Chemical Structure| 194413-58-6

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Semaxanib is an inhibitor of VEGFR2 (namely Flk-1 or KDR) with IC50 of 1.23 μM.

Synonyms: (Z)-SU5416

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of (Z)-Semaxanib

CAS No. :194413-58-6
Formula : C15H14N2O
M.W : 238.28
SMILES Code : O=C1NC2=C(C=CC=C2)/C1=C/C3=C(C)C=C(C)N3
Synonyms :
(Z)-SU5416
MDL No. :MFCD09763655
InChI Key :WUWDLXZGHZSWQZ-WQLSENKSSA-N
Pubchem ID :5329098

Safety of (Z)-Semaxanib

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H317-H319
Precautionary Statements:P280-P305+P351+P338

Related Pathways of (Z)-Semaxanib

RTK

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
HPAECs 7.8 nM Inhibition of SCF-induced c-KIT autophosphorylation Eur Respir J. 2022 Dec 1;60(6):2102356
HLFs 29 nM Inhibition of HLFs proliferation Eur Respir J. 2022 Dec 1;60(6):2102356
HPASMCs 33 nM Inhibition of HPASMCs proliferation Eur Respir J. 2022 Dec 1;60(6):2102356
H1703 cells 32 nM Inhibition of H1703 cell proliferation Eur Respir J. 2022 Dec 1;60(6):2102356

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice (C57BL/6) SU5416/hypoxia-induced pulmonary hypertension model Oral gavage 20 mg/kg Once daily for two weeks Evaluate the therapeutic effect of MDM2 inhibitor JNJ-165 on pulmonary hypertension Circulation. 2020 Sep 22;142(12):1190-1204
Sprague-Dawley rats SU5416/hypoxia-induced pulmonary hypertension model Subcutaneous injection 20 mg/kg Single dose followed by 3 weeks hypoxia exposure Induced pulmonary hypertension with elevated right ventricular systolic pressure, right ventricular hypertrophy, and pulmonary vascular remodeling Am J Respir Crit Care Med. 2016 Nov 1;194(9):1140-1151
Sprague-Dawley rats R-SU rat model Subcutaneous injection 20 mg/kg Single dose,for 5 weeks To establish a novel rat model representing immune-vascular pathological events mimicking human PAH associated with autoimmune disorders. Results showed that R-SU rats exhibited severe PH phenotypes, including significantly elevated mean pulmonary arterial pressure and right ventricle hypertrophy. Eur Respir J. 2023 Jul 20;62(1):2300204

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

4.20mL

0.84mL

0.42mL

20.98mL

4.20mL

2.10mL

41.97mL

8.39mL

4.20mL

References

 

Historical Records

Categories